Last reviewed · How we verify
NCT07332104
The Application of Extracellular Vesicle Detection in Gastric Juice Based on Metamaterial Sensing in the Diagnosis of Gastric Cancer and Related Diseases
trial testing In vitro surface plasmon resonance detection in Gastric Cancer (GC) in 100 participants. Not yet recruiting.
15 December 2026
Quick facts
| Lead sponsor | Beijing Friendship Hospital |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 100 |
| Start date | 15 December 2025 |
| Primary completion | 15 December 2026 |
| Estimated completion | 15 December 2026 |
Drugs / interventions tested
- In vitro surface plasmon resonance detection
Conditions studied
- Gastric Cancer (GC) — all drugs for Gastric Cancer (GC) →
- Gastric Cancer (Diagnosis) — all drugs for Gastric Cancer (Diagnosis) →
Sponsor
Beijing Friendship Hospital
Who can join
Adults 40 to 70, any sex, with Gastric Cancer (GC) or Gastric Cancer (Diagnosis). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
After obtaining informed consent from the patients, all the medical history and treatment records of the patients who underwent gastroscopy since the onset of the disease, as well as gastric fluid samples, including laboratory and imaging data, were collected and recorded. The medical history and treatment records and gastric fluid samples were analyzed.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07332104
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Gastric Cancer (GC)
Currently open trials in the same condition.
- NCT07522320 — Costs of Opportunistic Upper Gastrointestinal Endoscopy and the Economic Burden of Gastric Cancer Management · active not recruiting
- NCT07311408 — SHR-1701 + Rivoceranib (± SHR-2554) in Advanced GC After First-Line Immunotherapy Failure · Phase 2 · recruiting
- NCT07366528 — Adjuvant Oxaliplatin Plus S-1 Versus Docetaxel Plus S-1 for Stage III Gastric Cancer · Phase 3 · recruiting
- NCT07313579 — Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) in Gastric Cancer · recruiting
- NCT07217704 — Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer. · Phase 3 · recruiting
Other Beijing Friendship Hospital trials
Trials by the same sponsor.
- NCT07453862 — Novel Calcium Channel Modulators in RLS and Variants: Efficacy & Safety · Phase 1 · recruiting
- NCT07397442 — Short-Course Radiotherapy Combined With Chemotherapy and Immunotherapy in Mid-Low Locally Advanced Rectal Cancer · Phase 2 · not yet recruiting
- NCT07393048 — Application and Exploration of Personalized ctDNA-MRD Detection Technology in Predicting the Efficacy of Neoadjuvant The · recruiting
- NCT07441850 — Digital Rehabilitation for Gastric Cancer Surgery After Neoadjuvant Therapy · NA · recruiting
- NCT07369739 — Golidocitinib Combined With Selinexor for CAEBVD · Phase 2, PHASE3 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07332104 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Beijing Friendship Hospital
- Last refreshed: 12 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07332104.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing